Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMF-219 in Type 1 Diabetes Mellitus
NCT06152042Phase 2Completed
- Sponsor
- Biomea Fusion
- Start
- Dec 2023
- Primary completion
- May 2025
- Modality
- Covalent Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of icovamenib in type 1 diabetes mellitus (T1D) (7 arms), sponsored by Biomea Fusion. Primary endpoint: Endogenous insulin secretion at 26 weeks. Started Dec 2023; status: completed.
02
Drugs
icovamenib
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT06152042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06152042.